made an impressive stock market debut on Monday, listing at a hefty premium over its issue price and underscoring strong investor confidence in the pharmaceutical company.
The stock opened at ₹1,452 on the BSE, marking a premium of 36.7 per cent over the price of ₹1,062, while on the NSE it debuted even stronger at ₹1,470, translating into a gain of about 38 per cent.
It ended at 1,438.40 on the NSE and at 1,437.20 on the BSE, after moderating between ₹1,413-1,499 level.
The robust listing followed overwhelming demand for the company’s initial public offering, which The ₹655.37 crore IPO was entirely an offer for sale, with existing shareholders, including Sepia Investments, Anchor Partners, Sage Investment Trust and promoters paring their stakes. Since the issue did not include a fresh component, the proceeds went to the selling shareholders rather than the company.
Priced in the band of ₹1,008 to ₹1,062 per share, the issue had already signalled strong interest during the anchor book, with Corona Remedies raising ₹195 crore from anchor investors ahead of the public offer. This early demand set the tone for a favourable response from institutional, non-institutional and retail investors during the subscription period.
On listing, the stock’s sharp premium reflected market expectations of steady growth prospects and confidence in the company’s established presence in the domestic pharmaceutical market. Given the scale of oversubscription and the strong debut across both exchanges, investors had anticipated a solid listing pop, which the stock comfortably delivered.
Going ahead, market participants will track Corona Remedies’ post-listing performance in the context of broader market conditions and the company’s ability to sustain growth and margins. While the stellar debut has rewarded IPO investors handsomely, analysts caution that near-term movements could be volatile as early investors book profits following the sharp gains on listing day.